New Delhi, 10 October: Bharat Biotech, which requested DCGI’s recommendation on the conduct of phase 3 clinical trials of its COVID-19 candidate vaccine, requested to provide comprehensive knowledge on the protection and immunogenicity of the ongoing Phase 2 trial, in addition to providing some clarifications. , before moving on to the next step.
The vaccine candidate, “Covaxin”, is developed through Bharat Biotech in collaboration with the Medical Research Council of India (ICMR).
According to officials, Hyderabad-based vaccine manufacturer filed an application with the Indian Drug Comptroller-General (DCGI) on 2 October, requesting permission for a randomized, double-blind, placebo-controlled multicenter trial of its COVID-19 candidate vaccine.
The firm’s request said the canopy would cover 28,500 subjects over the age of 18 and be held at 19 sites, including Delhi, Mumbai, Patna and Lucknow, in 10 states.
According to sources, Covaxin Phase 2 trial is underway and the dose has still been administered to volunteers at some sites.
Coronavirus: India registers 73,272 new COVID-19; India’s total reaches 6. 97 million
“The company presented the Protocol for Phase 3 clinical trials as an intermediate knowledge of phase 1 and 2 clinical trials,” one official said.
The Committee of Experts on The Subject (SEC) of the Central Organization for the Control of Pharmaceutical Standards (CDSCO) discussed the application on October 5.
“After careful deliberation, the committee considered that the design of the Phase 3 review is in principle satisfactory, for an explanation of the definition of asymptomatic, etc.
“However, the test should be initiated with an adequate known dose of immunogenicity knowledge and phase 2 protection. As a result, the company will need to present knowledge of immunogenicity and protection of the Phase 2 trial for review,” the panel said in its recommendations.
During its discussion, the SEC also noted that the vaccine was well tolerated in all dose equipment and that no serious adverse occasions have been reported to date, one source said.
The maximum non-unusual appearance caused pain at the injection site, which was transiently resolved, the source said.
The Phase 3 test application proposed a dose of 0. 5 ml on days 0 and 28, Resources said.
In addition, Bharat Biotech, a candidate vaccine developed through Zydus Cadila Ltd, is found in phase 2 human clinical trials.
The Pune-based Indian Serum Institute, which has partnered with AstraZeneca to manufacture the Oxford COVID-19 vaccine candidate, is conducting phase 2 and 3 human clinical trials with the candidate in India.